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Results 
 
Cornelia de Lange Syndrome [CdLS (MIM#122470)] is a rare multisystemic developmental disorder 
with an estimated incidence of 1/10,000 - 30,000 births. It is characterized by a typical phenotype that 
includes distinctive facial dysmorphism, hirsutism, growth and psychomotor developmental delay, limb 
abnormalities, and relatively frequent gastrointestinal and congenital heart defects [1,2].  
Mutations in the NIPBL gene [5p13.1 (MIM*608667)] have been identified in ~50% of patients, while 
mutations in SMC1A gene [Xp11.2 (MIM*300040)] account for ~5% of individuals with CdLS. Mutations 
have also been described in SMC3 [10q25 (MIM*606062)] [3,4]. More recently, individuals with 
alterations in the RAD21 gene [8q24.11 (MIM*606462)] were also found to develop a cohesinopathy, with 
a milder cognitive impairment. These genes encode proteins linked to the cohesin complex that mediates 
sister-chromatid cohesion. This complex is involved in global transcriptional regulation and repair of DNA 
double strand breaks [5]. 
The molecular and clinical characterization of Portuguese CdLS patients has been previously described, 
as well as the development of a Locus Specific Database for NIPBL [6]. This presentation is an update on 
the molecular findings of our patient cohort; in particular, new NIPBL mutations which include large 
deletions, and screening for mutations in SMC1A by high resolution melting curve analysis (HRM).  
a - SMC1A Accession number of cDNA reference sequence: NM_006306 
b -NIPBL Accession number of cDNA reference sequence: NM_133433.3  
Seq. – Sequencing;  HRM – High Resolution Melting;  
 
  
Patients and Methods 
SMC1A mutation 
We identified a previously described mutation in SMC1A c.1487G>A (p.Arg496His) in 
patient 1 (Fig. 1). The HRM technique was used for mutation scanning, 3 replicates of 
each sample were used to prevent false positives/negative results. Samples with 
consistent abnormal melting curves were sequenced. 
 
NIPBL mutations 
11 point mutations were identified upon sequencing including 3 novel mutations: 
c.68delC (causing a frame-shift), missense mutations c.6983C>G (p.Thr2328Arg) and 
c.7307C>T (p.Ala2436Val) (Fig. 2, 4 and 5). We suspect the existence of somatic 
mosaicism in case 4, since the c.1885C>T mutation is underrepresented as compared 
with the WT allele (Fig. 3). Two novel gross rearrangements were found by MLPA (Fig. 
7 and 8): one deletion covering the complete NIPBL gene in patient 13; and the other 
deletion spanning exons 31 to 47 of in case 14. 
 
 
 
 
The mutation detection rates in our cohort correspond to those cited in the literature (Fig. 9 and 10). Our results also corroborate the 
importance of using different techniques (especially MLPA for NIPBL) to attain higher mutation detection rates.  
  
The relatively small size of SMC1A exons and the limited number of SNPs allowed the use of HRM as a preliminary mutation screening 
method. This approach is more cost effective and time saving as compared to sequencing, especially considering the reduced number of 
cases with SMC1A mutations reported. 
  
Somatic mosaicism is probably underestimated in the literature and might explain some degree of phenotypic variability in some patients. 
This holds true for the c.1885C>T mutation that was originally reported in a Japanese CdLS patient with a severe phenotype -  our case 
(with suspected somatic mosaicism) was classified as moderate. 
  
Routine Sanger sequencing may not be sufficiently sensitive to detect low levels (<20%) of mutated alleles, leading to false negative results. 
We have shown that the use of HRM might be helpful to detect mutations in cases with somatic mosaicism. 
Table 1: Mutations found in a subset of our patient cohort 
Patient Mutations Location 
Predicted 
polypeptide 
change 
Variant/Origin Detection Type 
Clinical  
Phenotype [7] 
References 
SMC1A gene a 
1 c.1487G>A Exon 9 p.(Arg496His) de novo HRM/SEQ missense n.a. 
Deardorff et al 2007 
 
NIPBL gene b 
2 c.64+1G>A Exon 2 p.(?) de novo SEQ. splicing mild Borck et al 2004 [8] 
3 c.86del Exon 3 p.Pro29Hisfs*18 unknown SEQ. frameshift severe Novel 
4 c.1885C>T Exon 10  p.(Arg629*) unknown SEQ. 
nonsense 
mosaicism? 
moderate Myake et al 2005 [9] 
5 c.3316C>T Exon 12 p.(Arg1106*) de novo SEQ. nonsense mild Miyake et al 2005 
6 c.4422G>T   Exon 21 p.(Arg1474Ser) de novo SEQ. missense mild Oliveira et al 2010 
7 c.5471C>T Exon 29 p.(Ser1824Leu) unknown SEQ. missense mild Oliveira et al 2010 
8 c.6653_6655delATA Exon 39 p.(Asn2218del) de novo SEQ. deletion moderate Borck et al 2004 
9 c.6763+5G>T Intron 39 p.(?) unknown SEQ. splicing mild Krantz et al 2004 
10 c.6983C>G Exon 41 p.(Thr2328Arg) unknown SEQ. missense n.a. Novel 
11 c.7168G>A Exon 42 p.(Ala2390Thr) de novo SEQ. missense moderate Gillis 2004 [10] 
12 c.7307C>T Exon 43 p.(Ala2436Val) de novo SEQ. missense n.a. Novel 
13 c.(?_-481)_(*927_?)del 
Exon 1 
to 47 
p.(?) de novo MLPA 
large 
deletion 
severe Novel 
14 
c.(5710-?)_(*927+?)del  
 
Exon 31 
to 47 
p.(?) unknown MLPA 
large 
deletion 
severe Novel 
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Suspected mosaicism mutation in exon 10, detected in sequencing (left) and confirmed through 
HRM (top). 
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